Nanotechnology for the treatment of coronary in stent restenosis: A clinical perspective

Vascular Cell

Volumn 3, Issue , 2011, Pages

  McDowell, Garry ^a   Slevin, Mark ^b,c   Krupinski, Jerzy ^d  

^a EDGE HILL UNIVERSITY   (United Kingdom)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DEXAMETHASONE; MACROGOL; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; RAPAMYCIN;

ALOPECIA; CORONARY STENT; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; IN-STENT RESTENOSIS; NANOTECHNOLOGY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 84858272210     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-3-8     Document Type: Review

References (31)

1. Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localisation by confocal laser scanning microscopy and transmission electron microscopy. Westedt U, Barbu-Tudoran L, Schaper AK, Kalinowski M, Alfke H, Kissel T, AAPS Pharm Sc 2002 4 41
2. Recent advances with liposomes as pharmaceutical carriers. Torchilin VP, Nat Rev Drug Discov 2005 4 145 160 10.1038/nrd1632 15688077 (Pubitemid 40282557)
3. Macrophage depletion by clodronate containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Danenberg HD, Fishbein I, Gao J, Monkkanen J, Reich R, Gati I, Moerman E, Golomb G, Circulation 2002 106 599 605 10.1161/01.CIR.0000023532.98469.48 12147543 (Pubitemid 34827711)
4. Systemic depletion of macrophages by liposomal bisphosphonate reduces neointimal formation following balloon injury in rat carotid artery. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Monkkonen J, Gao J, Gathi I, Reichi R, Golomb G, J Cardiovasc Pharmacology 2003 42 671 9 10.1097/00005344-200311000-00014 (Pubitemid 37305987)
5. Site specific targeting of nanoparticle prednisolone reduces in stent restenosis in a rabbit model of established atheroma. Joner M, Morimoto K, Kasukawa H, Steigerwalk K, Men S, Natazawa G, John MC, Finn AV, Acampado E, Kolodgie FD, Gold HK, Virman R, Arterioscler Thromb Vasc Biol 2008 28 1960 6 10.1161/ATVBAHA.108.170662 18688017
6. Nanotechnology in cardiovascular medicine. Patel D, Bailey SR, Cath Cardiovasc Interv 2007 69 643 54 10.1002/ccd.21060 (Pubitemid 46581252)
7. Development of the polymer micelle carrier system for doxorubicin. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K, J Control Release 2001 74 295 302 10.1016/S0168-3659(01) 00341-8 11489509 (Pubitemid 32727635)
8. Targeted polymeric micelles for delivery of poorly soluble drugs. Torchilin VP, Cell Mol Life Sci 2004 61 2549 59 10.1007/s00018-004-4153-5 15526161 (Pubitemid 39591627)
9. Structure and design of polymeric surfactant based drug delivery systems. Torchilin VP, J Control Release 2001 73 137 72 10.1016/S0168-3659(01)00299-1 11516494 (Pubitemid 32544594)
10. Sustained intramural retention and regional redistribution following local vascular delivery of polylactic-coglycolic acid and liposomal nanoparticle formulations containing probucol. Klugherz BD, Meneveau N, Chen W, Wade-Whittaker F, Papandreou G, Levy R, Wilensky RL, J Cardiovasc Pharmacol Ther 1999 4 167 174 10.1177/107424849900400306 10684538 (Pubitemid 29418881)
11. Alendronate loaded nanoparticles deplete monocytes and attenuate restenosis. Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R, Danenberg HD, Golomb G, J Control Release 2006 113 23 30 10.1016/j.jconrel.2006. 03.010 16697068 (Pubitemid 43818160)
12. Nanospheres of a bisphosphonate attenuate intimal hyperplasia. Cohen-Sela E, Dangoor D, Epstein H, Gati I, Danenberg HD, Golomb G, Gao J, J Nanosci Nanotechnol 2006 6 3226 34 10.1166/jnn.2006.428 17048541 (Pubitemid 44580005)
13. Surface modified paclitaxel loaded nanoparticles as local delivery system for the prevention of vessel restenosis. Mei L, Song CX, Jin X, Che YZ, Jin Z, Sun HF, Yao Xue Xue Bao 2007 42 81 6 17520813
14. Poly (vinyl alcohol)-graft-poly (lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. Westedt U, Kalinowski M, Wittmer M, Merdan T, Unger F, Fuchs J, Schaller S, Bakowsky U, Kissel T, J Control Release 2007 119 41 51 10.1016/j.jconrel.2007.01.009 17346845 (Pubitemid 46561540)
15. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Deshpande D, Devalapally H, Amiji M, Pharm Res 2008 25 1936 47 10.1007/s11095-008-9614-3 18480968
16. Production and in vitro characterization of lisinopril loaded nanoparticles for the treatment of restenosis in stented coronary arteries. Varshosaz J, Soheili M, J Microencapsul 2008 25 478 86 10.1080/02652040802054679 19238723
17. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity. Cohen-Sela E, Teitlboim S, Chorny M, Koroukhov N, Danenberg HD, Gao J, Golomb G, J Pharm Sci 2009 98 452 62 10.1002/jps.21527
18. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Zou W, Cao G, Xi Y, Zhang N, Drug Deliv 2009 16 15 23 10.1080/10717540802481307 19555304
19. Release of anti-restenosis drugs from poly (ethylene oxide)-poly(DL- lactic-co-glycolic acid) nanoparticles. Zweers ML, Engbers GH, Grijpma DW, Feijen J, J Control Release 2006 114 317 24 10.1016/j.jconrel.2006.05.021 16884807 (Pubitemid 44310811)
20. Biodegradable sirolimus loaded poly(lactide) nanoparticles as drug delivery systems for the prevention of in-stent restenosis in coronary stent application. Luderer F, Lobler M, Rohm HW, Gocke C, Kunna K, Kock K, Kroemer HK, Westschies W, Shmitz KP, Sternberg K, J Biomater Appl 2010 20237179
21. Formulation of nanoparticle eluting stents by a cationic electrodesposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle eluting stents in porcine coronary arteries. Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, Hara K, Tsujimoto H, Tominagu R, Sunagawa K, JACC Cardiovasc Interv 2009 2 277 83 10.1016/j.jcin.2008.08.023 19463437
22. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. Fishbein I, Chorny M, Robinovich L, Banai S, Gati I, Golomb G, J Contol Release 2000 65 221 9 10.1016/S0168-3659(99)00244-8 (Pubitemid 30122927)
23. PDGF receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle call growth in vitro and reduced neointimal formation after balloon angioplasty in swine. Banai S, Wolf Y, Golomb G, Pearla A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarouichi G, Rabinovich L, Levitzki A, Gertz SD, Circulation 1998 97 1960 9 9609090 (Pubitemid 28222191)
24. Locally delivered nanoencapsulated tyrphostin (AGL2043) reduces neointimal formation in balloon injured rat carotid and stented porcine coronary arteries. Banai S, Chorney M, Gertz SD, Fishbein I, Gao J, Perez L, Lazarovichi G, Gazit A, Levitzki A, Golomb G, Biomaterials 2005 26 451 61 10.1016/j.biomaterials.2004.02.040 15275819 (Pubitemid 38951112)
25. Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells and smooth muscle cells. Nguyen KT, Shukla KP, Moctezuma M, Braden AR, Zhou J, Hu Z, Tang L, J Biomed Mater Res A 2009 88 1022 30 18404709
26. Inhibition of apoptosis through localised delivery of rapamycin loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V, Circ cardiovasc Interv 2008 1 209 16 10.1161/CIRCINTERVENTIONS.108.830018 20031680
27. Sustained reduction of in stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R, Circulation 2002 106 1195 8 10.1161/01.CIR.0000032141.31476.15 12208792 (Pubitemid 34988635)
28. Targeted antiproliferative drug delivery to vascular smooth muscle cells with magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen LK, Fahrhop RW, Scherrer DE, Wickline SA, Circulation 2002 106 2842 7 10.1161/01.CIR.0000044020.27990.32 12451012 (Pubitemid 35396985)
29. Intramural delivery of rapamycin with V3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Carruthers SD, Wickline SA, Lanza GM, Arteriosler Thromb Vasc Biol 2008 28 820 6 10.1161/ATVBAHA.107.156281 (Pubitemid 351544094)
30. Targeting stents with local delivery of paclitaxel loaded magnetic nanoparticles using uniform fields. Chorny M, Fishbein I, Yellen BB, Alferier IS, Backay M, Ganta S, Adamo R, Amiji M, Friedman G, Levy RJ, Proc Natl Acad Sci USA 2010 107 8346 51 10.1073/pnas.0909506107 20404175
31. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis-I (SNAPIST-I): a first in human safety and dose finding study. Margolis J, McDonald J, Heuser R, Klkinke P, Waksman R, Virmani R, Desai N, Hilton D, Clin Cardiol 2007 30 165 70 10.1002/clc.20066 17443649 (Pubitemid 46642054)